ClinicalTrials.gg
CompletedNCT03453801SLVP030Updated Feb 13, 2020

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

A Phase 1 interventional study of Fluzone® and FluMist® in Influenza and Healthy, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 6 Months to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-13.

Sponsored by Stanford University · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2019, 7 years 10 months ago, and no results have been posted to the registry.
  • Registered 3 years 4 months after the study started (first participant enrolled Sep 2014, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
6 Months to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing FluMist in Influenza, Human — 4 open to participants now, 7 under way, none of them phase 3. FluMist · Influenza, Human.

Enrollment
17th of 37
80 · median 72
Started
2014
with 5 others
Phase 1
7 of 37
none open now
Registered
30th of 37
by date
Lead sponsor
10 of 37
Stanford University

Among the 37 studies testing FluMist in Influenza, Human, this one is the 17th largest by enrollment, is one of 6 that started in 2014, is one of 7 in phase 1, and was the 30th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 37 studies testing FluMist in Influenza, Human are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About FluMist

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 6 Months to 10 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing FluMist in Influenza, Human, or all of them as a file.
02

Study summary

The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.

Read the detailed description

This is a Phase I study of up to 100 healthy children, ages 6 months to 10 years of age, who will receive either Flumist® live, attenuated influenza virus vaccine, quadrivalent (LAIV4) or the current Fluzone® inactivated influenza vaccine, quadrivalent (IIV4). The volunteers will be enrolled into one of 3 Groups. Volunteers will return each year until 2018-2019 for annual flu immunizations and study visits. Questionnaires will be administered annually to record demographic characteristics, vaccination history, exposure to animals, day care and medically attended illness. There are no exclusions for gender, ethnicity or race.

Volunteers in the Non-twin Flu/MMRV naive group will also receive the measles, mumps, rubella and varicella (MMRV) vaccine at approximately 12-15 months of age (to be administered by the volunteers' personal pediatrician, not as a study vaccine). They will then come for a study visit to collect blood 60 days later.

Each twin is counted as a single participant. All reporting numbers reflect the number of participants, not the number of twin pairs.

03

Conditions studied

  • Influenza
  • Healthy

Browse trials for

Keywords

  • Inactivated, influenza vaccine quadrivalent
  • Live, attenuated influenza vaccine quadrivalent
  • Young children
  • Identical twins
04

Who can participate

Ages eligible
6 Months to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Otherwise healthy non-twins 6 months - 10 years old, or 2-5 year old identical (MZ) twins.
  2. Willing to complete the process (including assent for minors 7 years old and above).
  3. Availability for follow-up for the planned duration of the study - annually until 2018-2019 influenza vaccination season
  4. Acceptable medical history by review of inclusion/exclusion criteria and vital signs.
  5. Non-twin flu/MMRV naive group: Willing to have primary care physician immunize child with the MMRV vaccine and return for a study visit approximately 60 days later.

Exclusion criteria

Exclusion Criteria:

  1. Prior off-study vaccination with the current year's seasonal influenza vaccine.
  2. Life-threatening reactions to previous influenza vaccinations
  3. Allergy to egg or egg products, or to vaccine components
  4. Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
  5. History of immunodeficiency (including infection)
  6. Known or suspected impairment of immunologic function, including, but not limited to, liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
  7. Chronic or C.
  8. Recent or current use of medication, including systemic (corticosteroid nasal sprays and topical steroids are permissible in all groups; inhaled steroid use is not permissible)
  9. disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
  10. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
  11. Receipt of blood or blood products within the past 6 months or planned used during the study.
  12. Receipt of Inactivated vaccine 14 days prior to study enrollment, or planned vaccinations prior to completion of last study visit ( \~ 28 Day after study vaccination)
  13. Receipt of live, attenuated vaccine within 60 days prior to enrollment of planned vaccination prior to completion of last study visit (\~ 28 Day after study vaccination)
  14. Need for allergy immunization (that cannot be postponed) during the study period.
  15. History of Guillain-Barré syndrome
  16. Use of agents within 30 days prior to enrollment or planned use during the study.
  17. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or planned donation prior to completion of the last visit.
  18. Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    MZ twins 2-5 yo

    Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.

    Biological: Fluzone® · Biological: FluMist®

  • Experimental
    Non-twins 6 mo-10 yo

    Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.

    Biological: Fluzone® · Biological: FluMist®

  • Experimental
    Non-twins 6-12 mo Flu/MMRV Naïve

    Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.

    Biological: Fluzone®

Interventions

  • BiologicalFluzone®

    Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.

    Also known as: IIV4

  • BiologicalFluMist®

    FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray

    Also known as: LAIV4

06

What researchers measure

Primary outcomes

  1. Frequency of antigen-specific T memory phenotype cells (TMP)

    The percentage of cells with the various antigen-specific T memory phenotypes will be determined.

    Time frame: Day 0 to Day 60

Secondary outcomes

  1. T cell receptor (TCR) repertoire analysis deep phenotyping by mass cytometry (CyTOF)

    The TCR repertoire encompasses the different sub-types of T-cell receptors of the immune system.

    Time frame: Day 0 to Day 60

  2. Deep phenotyping by mass cytometry (CyTOF)

    Deep phenotyping is the analysis of phenotypic abnormalities of the individual components of the phenotype.

    Time frame: Day 0 to Day 60

07

Study locations

1 site
  • Stanford University
    Stanford, California 94304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jan 2019, 51 months.

Of 54 non-industry phase 1 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 51 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2018
First posted
Mar 5, 2018
StartActual
Sep 30, 2014
Primary completionActual
Jan 14, 2019
CompletionActual
Jan 14, 2019
Last update
Feb 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03453801
Responsible party
Philip Grant (Assistant Professor of Medicine (Infectious Diseases), Stanford University) — Principal investigator
First posted
Mar 5, 2018
Start date
Sep 30, 2014
Primary completion
Jan 14, 2019
Completion
Jan 14, 2019
Last update
Feb 13, 2020

Study contacts

Cornelia L Dekker, MD
principal investigator · Stanford University
Mark M Davis, PhD
principal investigator · Stanford University
Philip M Grant, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion